Compare KT & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KT | ICLR |
|---|---|---|
| Founded | 1981 | 1990 |
| Country | South Korea | Ireland |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 9.3B |
| IPO Year | 2002 | 2001 |
| Metric | KT | ICLR |
|---|---|---|
| Price | $21.18 | $124.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $178.62 |
| AVG Volume (30 Days) | 919.2K | ★ 1.4M |
| Earning Date | 06-16-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.09 | N/A |
| Revenue Next Year | $2.13 | N/A |
| P/E Ratio | $15.73 | ★ $12.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.54 | $66.57 |
| 52 Week High | $24.58 | $211.00 |
| Indicator | KT | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 42.08 | 62.35 |
| Support Level | $21.12 | $99.11 |
| Resistance Level | $21.29 | $193.87 |
| Average True Range (ATR) | 0.31 | 6.49 |
| MACD | -0.06 | 1.65 |
| Stochastic Oscillator | 17.80 | 83.93 |
KT is South Korea's largest fixed-line telecom operator, with around 11.5 million fixed-line broadband customers and 9.5 million IPTV customers, and is the second-largest wireless operator with 28 million subscribers. Additionally, it has a number of nontelecom businesses, including real estate, payment processing, artificial intelligence, and IDC/cloud services, many of which are the focus of its growth strategy. The company was formed from the previously government-owned, monopoly telecom business and was listed in 1998. After selling its mobile business in 1994 (forming its mobile competitor, SK Telecom), KT created its own mobile operator in 1997.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.